Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-06-26
2007-06-26
Balasubramanian, Venkataraman (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S274000, C514S252010, C514S252100, C514S241000, C544S316000, C544S331000, C544S180000, C544S238000
Reexamination Certificate
active
10524462
ABSTRACT:
The invention provides the compounds of formula (I)or a pharmaceutically acceptable salt thereof.Compounds of formula (I) are potent and selective inhibitors of COX-2 and are of use in the treatment of the pain, fever and inflammation of a variety of conditions and diseases.
REFERENCES:
patent: 3149109 (1964-09-01), Neustaedter et al.
patent: 3592895 (1971-07-01), Hepworth et al.
patent: 5474995 (1995-12-01), Ducharme et al.
patent: 5760068 (1998-06-01), Talley et al.
patent: 5849758 (1998-12-01), Kleemann et al.
patent: 5972842 (1999-10-01), Maier et al.
patent: 5972986 (1999-10-01), Seibert et al.
patent: 5985886 (1999-11-01), Elliott et al.
patent: 6020343 (2000-02-01), Belley et al.
patent: 6121202 (2000-09-01), Karp et al.
patent: 6153619 (2000-11-01), Wood et al.
patent: 6248892 (2001-06-01), Noerenberg et al.
patent: 6306866 (2001-10-01), Wood et al.
patent: 6313072 (2001-11-01), Scheiblich et al.
patent: 6355799 (2002-03-01), Gupta et al.
patent: 6451794 (2002-09-01), Beswick et al.
patent: 6498166 (2002-12-01), Campbell et al.
patent: 6756498 (2004-06-01), Fitzgerald et al.
patent: 6759413 (2004-07-01), Mangel et al.
patent: 6780869 (2004-08-01), Green et al.
patent: 6780870 (2004-08-01), Carter et al.
patent: 6803463 (2004-10-01), Mathews et al.
patent: 6831097 (2004-12-01), Beswick et al.
patent: 6861249 (2005-03-01), Kent
patent: 2003/0013717 (2003-01-01), Mangel et al.
patent: 2003/0018023 (2003-01-01), Pinto et al.
patent: 19651099 (1998-06-01), None
patent: 19708928 (1998-09-01), None
patent: 19909541 (1999-03-01), None
patent: 19831246 (2000-01-01), None
patent: 0723960 (1996-07-01), None
patent: 0820996 (1998-01-01), None
patent: 9241161 (1997-09-01), None
patent: 2001252044 (1999-11-01), None
patent: 2000026421 (2000-01-01), None
patent: 2001081074 (2001-03-01), None
patent: WO 9607641 (1996-03-01), None
patent: WO 96 24585 (1996-08-01), None
patent: WO 96 41625 (1996-12-01), None
patent: WO 96 41645 (1996-12-01), None
patent: WO 97/38996 (1997-10-01), None
patent: WO 98/03484 (1998-01-01), None
patent: WO 98 16227 (1998-04-01), None
patent: WO 98/24782 (1998-06-01), None
patent: WO 99 01439 (1999-01-01), None
patent: WO 99/12930 (1999-03-01), None
patent: WO 99/55668 (1999-04-01), None
patent: WO 99/21837 (1999-05-01), None
patent: WO 00/26216 (2000-05-01), None
patent: WO 00/47553 (2000-08-01), None
patent: WO 00/52008 (2000-09-01), None
patent: WO 01/38311 (2001-05-01), None
patent: WO 01/41760 (2001-06-01), None
patent: WO 01/45703 (2001-06-01), None
patent: WO 01/46194 (2001-06-01), None
patent: WO 01/56573 (2001-08-01), None
patent: WO 01/58881 (2001-08-01), None
patent: WO 01/62233 (2001-08-01), None
patent: WO 01/83479 (2001-11-01), None
patent: WO 02/00647 (2002-01-01), None
patent: WO 02/00655 (2002-01-01), None
patent: WO 02/18374 (2002-05-01), None
patent: WO 02/44137 (2002-06-01), None
patent: WO 02/55484 (2002-07-01), None
patent: WO 02/59122 (2002-08-01), None
patent: WO 02/096427 (2002-12-01), None
patent: WO 02/96427 (2002-12-01), None
patent: WO 02/096885 (2002-12-01), None
patent: WO 02/096886 (2002-12-01), None
patent: WO 02/100838 (2002-12-01), None
patent: WO 03/04472 (2003-01-01), None
patent: WO 03/14091 (2003-02-01), None
patent: WO 03/14092 (2003-02-01), None
patent: WO 03/22219 (2003-03-01), None
patent: WO 03/77920 (2003-09-01), None
patent: WO 2004/018452 (2004-03-01), None
patent: WO 2004/024691 (2004-03-01), None
patent: WO 2004/048344 (2004-06-01), None
patent: WO 2005/016924 (2005-02-01), None
Freston, American Journal of Medicine 107(6A): 79S-89S, 1999.
Naesdal et al., European Journal of Gastroenterology & Hepatology 13(12): 1401-1406, 2001.
Stichtenoth et al., Drugs, 63(1): 33-45, 2003.
Hochberg MC., Am. J. Manag. Care., 8(17Suppl):S502-517, 2002.
Stanghellini et al. “Risk Indicators of Delayed Gastric Emptying of Solids in Patients with Functional Dyspepsia.” Gastroenterology, 110(4), 1986, pp. 1036-1042.
Casanova, B., et al. “A Critical Review of the Current Pathogenesis of Multiple Sclerosis and Possible Future Trends.” PubMed Abstract (Rev. Neurol. 28(9), May 1999, pp. 909-915.
Stichtenoth, D.O., et al. “The Second Generation of COX-2 Inhibitors.” Drugs, 63(1), 2003, pp. 33-45.
FDA Label for Celebrex, 20-998, Jun. 29, 2005.
FDA Label for Vioxx, 21-042, May 20, 1999.
Damasio, A.R., et al. Alzheimer's Disease and Related Dementias, Cecil Textbook of Medicine, vol. 2, pp. 1992-1996, 1996.
Douglas, R.G., Jr. Introduction to Viral Diseases: Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 1739-1747, 1996.
Freston, J.W., et al. Rationalizing Cyclooxygenase (COX) Inhibition for Maximal Efficacy and Minimal Adverse Events + Abstract, Am. J. Med. 107(6A):78S-88S; Discussion 89S), Dec. 1999.
Layzer, R.B., et al. Degenerative Diseases of the Nervous System, Cecil Textbook of Medicine, 20thEdition, vol. 2, pp. 2050-2057, 1996.
Naesdal, J. et al. “Gastro-Duodenal Protection in an Era of Cyclo-Oxygenase-2-Selective Nonsteroidal Anti-inflammatory Drugs.” PubMed Abstract, Eur J Gastroenterol Hepatol, 13(12):1401-1406, Dec. 2001.
Simone, JV., et al. Oncology: Introduction, Cecil Textbook of Medicine, 20thEdition, vol. 1, pp. 1004-1010, 1996.
Bravi Gianpaolo
Weingarten Gordon
Balasubramanian Venkataraman
Glaxo Group Limited
Young J. Scott
LandOfFree
Pyrimidine derivative as selective COX-2 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrimidine derivative as selective COX-2 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidine derivative as selective COX-2 inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861922